• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
171378 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

  a. C& ?8 q0 I9 C  z9 y2 i$ k/ I可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  , R- M8 h3 b& M9 C( E2 {1 M, U$ @

% m% h3 y# }* R- G$ c
6 k/ n; I4 y+ G: C( wSub-category:; l' [" v8 [; w( M
Molecular Targets
- D& D0 {) R5 {5 a+ Y5 Q' R9 i2 M1 D- d

4 q2 i0 u0 t1 ]5 T  t  rCategory:
  s. b9 p  b! BTumor Biology * a3 p3 m4 O$ ?6 |1 ?; _

, ~9 e. N( R2 d7 V
0 y/ Y, c$ S% w/ e/ fMeeting:+ d2 Q1 h7 ^  c8 w5 r8 _
2011 ASCO Annual Meeting
9 Z, J% q: w% |# ?7 h3 d0 C" X* r) n" M2 x* W  H( C
$ [4 J- o+ _, i* b/ d
Session Type and Session Title:
/ e4 ]& d- Z- s9 rPoster Discussion Session, Tumor Biology 5 r  m8 H& \5 B  S( w0 q
3 E9 }7 H& R1 R  v& [
- \) O' m9 r+ r& H7 x- I! [  N
Abstract No:6 y  u6 Q# T, _$ n, u3 u5 O" [
10517
5 f% ?8 u$ X% ?$ Z3 i+ q8 F: i2 H. ^1 h

' f8 l7 p6 m8 }Citation:6 C, h8 S4 H0 g& F7 i/ g
J Clin Oncol 29: 2011 (suppl; abstr 10517)
# f  w0 }: Z# p8 \0 ]' e1 C4 x4 C3 M: Q# s1 k; Q

  O) c! V* `# u4 t2 N' uAuthor(s):
1 p/ O$ W8 d3 r4 M" {, X7 gJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 6 A/ H/ ]- [  h
1 e& x3 A# l3 Q
7 G# I9 q1 e7 z

: [5 I  v( h) v. x8 ^! J6 p* CAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.6 q! q, g* x( i' G0 `

/ x: ]- \9 f. }" A6 oAbstract Disclosures
( O. ~" h* b) R
1 A$ k, f$ d/ D( R3 |' UAbstract:0 k( Q0 I- u+ b' p

7 Z  S1 q7 o; Q$ n8 q
" S% L4 `! N0 l3 G2 f) B. p2 }Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.4 U& t! I+ i) p. Z+ e3 H! h( W

6 ^' x0 v( c! h- M6 G7 {
. a$ M1 v- E9 _( r
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
! F. X3 |( [5 n; B没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
2 h4 W4 C' c6 C( U* p" W
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
/ B7 A  i' P% }# l: }. l0 m易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
( d3 }/ W; d+ i6 G1 |4 WALK一个指标医院要900多 ...
$ B! Z/ `; C$ \/ _( d* ^7 \+ K
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
3 a7 T1 o, D: r# B7 H' k. x
8 c5 W& o/ S4 s3 m3 Y: b4 c. O5 M现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表